Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sequential single-agent doxorubicin versus paclitaxel in palpable breast cancer
ISRCTN12618919Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2000
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doxorubicin and paclitaxel in breast cancer (2 arms), sponsored by National Cancer Institute. Started Jun 2000; status: completed.
02
Drugs
doxorubicinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN12618919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12618919.